Ultragenyx Pharmaceutical Inc. (RARE)

NMS – Real Time Price. Currency in USD

26.70

-0.26 (-0.96%)

Market open: Aug 12, 2026, 11:28 AM EDT

26.90

-0.06 (-0.22%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

05.08.2026

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

RARE beats Q2 earnings estimates as revenues surge year over year to a record quarterly high, driven by higher product sales across its portfolio.

05.08.2026

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript

05.08.2026

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

Ultragenyx Pharmaceutical NASDAQ: RARE reported second-quarter 2026 revenue of $214 million, led by growth across its commercial rare-disease portfolio, while the company prepared for potential regulatory decisions on two gene therapies and a late-stage data readout in Angelman syndrome.

05.08.2026

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

05.08.2026

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx (RARE) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to a loss of $1.17 per share a year ago.

04.08.2026

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Second quarter total revenue of $214 million, Crysvita® revenue of $156 million and Dojolvi® revenue of $27 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A expenses to be flat to slightly down versus 2025; remain on path to profitability in 2027 Catalysts in second half of 2026 include two PDUFA dates and pivotal data readout from GTX-102 Phase 3 Aspire study for Angelman syndrome NOVATO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended June 30, 2026 and reaffirmed its financial guidance for 2026.

Videos

No Data

There is no data to display

Press releases

04.08.2026

Ultragenyx Pharmaceutical Inc. (RARE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Videos

No Data

Press releases

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Videos

No Data

Press releases

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Search stocks

Ultragenyx Pharmaceutical Inc. (RARE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Videos

No Data

Press releases

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Videos

No Data

Press releases

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update